A multistakeholder call for belzutifan biomarker data in advanced pheochromocytoma and paraganglioma

Trends in Endocrinology and Metabolism 2026 Open access

Read full text
Authors: Rodrigo Almeida Toledo, Carlota Arenillas, Patricia L. M. Dahia, Judith Favier, Mercedes Robledo, Anand Vaidya, Henri H.J.L.M. Timmers, Cristina L Ronchi, Frederic Castinetti, Roderick Clifton-Bligh, Chritina Pamporaki, Ruth T. Casey
+23 more Madson Q. Almeida, Louis J. Maher, Hussam Alkaissi, Jorge Hernando, Akiyo Tanabe, Isabelle Bourdeau, Cynthia M. Estrada-Zúñiga, Marta Araujo-Castro, Anli Tong, Amanda Dusing, Mar Ayllón, Anna‐Karin Gustavsson, Joanna Grey, Anna Greene, Aaron R. Hansen, Irina Bancos, S A Akker, William F. Young, Svenja Nölting, Hans K. Ghayee, Graeme Eisenhofer, Lenders Jw, Karel Pacák
DOI: 10.1016/j.tem.2026.06.007
Cited by: 1
References: 14

Abstract

The HIF-2α inhibitor belzutifan was recently U.S. Food and Drug Administration (FDA)-approved for advanced pheochromocytoma/paraganglioma. This multistakeholder article calls for clinical-trial genomic correlates and outcome data to clarify efficacy across these molecularly heterogeneous neuroendocrine tumors.

Fields of Study & Subjects

Adrenal and Paraganglionic Tumors Pituitary Gland Disorders and Treatments Hormonal Regulation and Hypertension

Publication details

Journal / source
Trends in Endocrinology and Metabolism
Publisher
Elsevier BV
Volume
37
Issue
9
Pages
805–809
Publication date
21 July 2026
Language
EN